Citigroup’s Editas Medicine EDIT Stock Holding History

Citigroup’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-184,700	Closed	-$12.9M	–	6533
2020 Q4	$12.9M	Buy	184,700 +138,500	+300%	+$5.69M	0.01%	1349
2020 Q3	$1.3M	Sell	46,200 -19,600	-30%	-$638K	﹤0.01%	3042
2020 Q2	$1.95M	Buy	65,800 +58,700	+827%	+$1.53M	﹤0.01%	2838
2020 Q1	$141K	Sell	7,100 -15,900	-69%	-$401K	﹤0.01%	5042
2019 Q4	$681K	Buy	23,000 +5,000	+28%	+$125K	﹤0.01%	4135
2019 Q3	$409K	Buy	18,000 +4,800	+36%	+$119K	﹤0.01%	4530
2019 Q2	$327K	Sell	13,200 -4,000	-23%	-$95.5K	﹤0.01%	4846
2019 Q1	$421K	Buy	17,200 +4,600	+37%	+$104K	﹤0.01%	4359
2018 Q4	$287K	Buy	12,600 +4,100	+48%	+$112K	﹤0.01%	4666
2018 Q3	$270K	Sell	8,500 -5,800	-41%	-$187K	﹤0.01%	4934
2018 Q2	$512K	Buy	14,300 +13,100	+1,092%	+$464K	﹤0.01%	4076
2018 Q1	$40K	Buy	+1,200	New	+$42.8K	﹤0.01%	6327

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup's EDIT Position: Q1 2026 in Review

Citigroup increased its Editas Medicine (EDIT) stake by 45% in Q1 2026, buying an estimated $4.79K and bringing the position to 7,298 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #4864.

Citigroup first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $8.12M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Citigroup held 7,298 shares of Editas Medicine worth $18K as of Q1 2026.
Citigroup bought 2,261 Editas Medicine shares in Q1 2026, an estimated $4.79K.
Editas Medicine made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4864 holding.
Citigroup first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
Citigroup's Editas Medicine position peaked at $8.12M in Q2 2021.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.